The most common comorbidities found in patients with psoriasis are hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.
Researchers sought to analyze long-term and real-world outcome data in patients with moderate-to-severe psoriasis after starting biologic treatment.
Presence of psoriatic arthritis, weight, employment status, baseline disease severity affect the selection of first-line biologic treatment.
Nearly 50% of patients with psoriatic arthritis report elevated levels of fatigue.
The biosimilar has also been approved for Crohn's disease, ulcerative colitis, and ankylosing spondylitis.
Mild, moderate, and severe psoriasis can patients' quality of life and workplace productivity.
Patients with psoriasis are more likely to have an abdominal aortic aneurysm, with the likelihood increasing with more severe psoriasis.
Researchers found that the annual incidence rate of PsA was 2.7 cases per 100 psoriasis patients.
A number of therapeutic options exist for patients with psoriasis, including phototherapy and systemic and biologic agents.
Escalating prices were found across all categories of dermatologic drugs, including anti-infective medications and treatments for psoriasis and rosacea.
Only 10% of Medicare beneficiaries were receiving biologic treatments for psoriasis.
El Nino and La Nina have been linked to increases in actinic keratosis, rosacea, dermatitis, psoriasis, and varicella, among other dermatologic conditions.
Patients with psoriasis or psoriatic arthritis who undergo bariatric surgery may see significant improvements in disease severity.
Biologic agents associated with high risk of hepatitis B virus flares in patients with psoriasis or rheumatoid arthritisNovember 14, 2015
The use of biologic agents in treatment of patients rheumatoid arthritis or psoriasis is associated with a significant risk of heptatis B flares.
Combination use of methotrexate and golimumab may significantly improve psoriatic arthritis symptomsNovember 11, 2015
Using methotrexate and golimumab in combination may significantly improve some symptoms among patients diagnoes with psoriatic arthritis.
Several controlled clinical trials have proven the efficacy of golimumab in reducing symptom severity and improving disease outcomes in patients with psoriatic arthritis.
Many people think that psoriasis is contagious or that it is caused by an infection, which contribute to the stigma.
The most severe cases of psoriasis can increase vascular inflammation levels by as much as 41%.
Another study linked psoriasis to major depression, but the results still do not show a causal effect.
Two studies indicate that brodalumab and secukinumab had significant benefits for patients with psoriasis or psoriatic arthritis.
Patients with psoriasis, especially those with psoriatic arthritis, have an increased risk of arrhythmia.
Adding kunzea oil to topical psoriasis treatments did not improve their efficacy.
Patients with psoriasis who take biologic medications report more overall treatment satisfaction.
The safety and efficacy of 56 treatment courses for pediatric psoriasis were evaluated.
Women with psoriasis and psoriatic arthritis have an increased risk of depression.
Alefacept, a psoriasis treatment, can help preserve pancreas function in type 1 diabetes.
Psoriasis patients exposed to trauma have an increased risk for psoriatic arthritis.
Patients and practitioners require significant education about psoriasis, including information on treatment options.
The monoclonal antibody ixekizumab was more effective than other treatments for treating psoriasis.
Guselkumab was more effective than standard psoriasis treatment but had higher rates of pneumonia.